Biologic Therapeutics in the Treatment of Psoriasis. Part 1: Review

Langley, Richard; Gupta, Aditya K.; Cherman, Andrea M.; Inniss, Kimberley A.

doi:10.2310/7750.2006.00060a

Cited by 18 publications

(20 citation statements)

References 79 publications

(180 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although biologic-immune-response modifiers that specifically target key mechanisms of the pathogenesis of psoriasis have been shown to be effective [50][51][52], the costs of these drugs are prohibitively expensive for use in resource limited settings. Chloroquine on the other hand is cheap, easy to use and is a widely available drug.…”

Section: Resultsmentioning

confidence: 99%

Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine

Shihab¹,

Feld

Lutwama

et al. 2009

TOIDJ

View full text Add to dashboard Cite

Abstract:The effect of chloroquine in the treatment of psoriasis remains controversial. Treatment of psoriasis in HIV infection is not well described. Chloroquine has been shown to have direct effects on both the Human Immunodeficiency Virus (HIV) and on the psoriasis disease process. The effect of chloroquine in HIV infected patients with psoriasis has not been well studied.We report on the effect of chloroquine on psoriasis-like lesions in three HIV infected patients who were not on antiretroviral therapy. Three consecutive HIV positive patients with CD4 cell count below 200cells/mm 3 had unequivocal improvement of their psoriasis-like lesions after 2 weeks of a daily dose of 150mg of chloroquine.In conclusion, chloroquine may be useful in the treatment of psoriasis-like lesions in patients with HIV infection particularly in resource poor settings. Ideally, a controlled clinical trial will be needed to confirm this.

show abstract

Section: Resultsmentioning

confidence: 99%

Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine

Shihab¹,

Feld

Lutwama

et al. 2009

TOIDJ

View full text Add to dashboard Cite

show abstract

“…Jusqu'à une date récente, peu de revues systéma-tiques et de méta-analyses sur l'efficacité des anti-TNF-␣ avaient été publiées [24][25][26][27][28]. Elles n'étaient pas exhaustives [25,26,28], ou portaient sur un faible nombre de publications [23,27,28].…”

Section: Discussionunclassified

“…Elles n'étaient pas exhaustives [25,26,28], ou portaient sur un faible nombre de publications [23,27,28]. Une revue systématique de la Collaboration Cochrane sur les traitements biologiques dans le psoriasis cutané en plaque est en cours [29].…”

Section: Discussionunclassified

Efficacité des anti-TNF-α dans le psoriasis : revue systématique et représentation graphique

Levy-Roy

Porcher

Fonclare

et al. 2009

Annales de Dermatologie et de Vénéréologie

View full text Add to dashboard Cite

“…Phase II and phase III clinical studies reported infusion reactions (defined as any adverse event occurring during 1 h of administration) as the most common adverse events [3,4,5,6,7,8]. The most common reactions were chills, headache, flushing, nausea, dyspnea and high blood pressure.…”

Section: Introductionmentioning

confidence: 99%

“…Interestingly, postmarketing observations of psychosis, suicide and panic attack have been described [8]. The latter is a clinical manifestation of anxiety characterized by brief episodes of intense fear or apprehension developing without apparent reason or triggers [9].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Management of Panic Attacks during Infliximab Infusion in Psoriatic Patients

et al. 2012

View full text Add to dashboard Cite

Background: Psoriasis is a chronic, inflammatory skin disease associated with anxiety and depression. Infliximab (IFX) is a human/mouse chimeric anti-TNF-α antibody effective in the treatment of psoriasis. Objective: The aim of this study was to evaluate the prevalence of panic disorders in psoriatic patients during IFX infusions. Methods: A retrospective study was performed on patients affected with psoriasis who were treated with IFX from 2002 to 2011 at a single center. Panic disorders were defined using the clinical criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. A population of dermatological patients under treatment with IVG, rituximab, apheresis, intravenous corticosteroids and antibiotics was considered as the control group. Results: A total of 141 patients were evaluated. Of these, 6 (4.25%) experienced panic attacks during the infusion; 16 (11.3%) had a medical history of panic attack and of those 5/16 (31%) experienced panic attacks during IFX infusion. In the control group panic attacks were not recorded. Conclusion: We describe 6 cases of patients in whom panic attacks were triggered by IFX infusion. Premedication with oral benzodiazepine and a slow rate of infusion is recommended.

show abstract

Biologic Therapeutics in the Treatment of Psoriasis. Part 1: Review

Abstract: These novel biologics offer an intriguing and effective treatment option for patients with moderate to severe psoriasis.

Cited by 18 publications

References 79 publications

Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine

Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine

Efficacité des anti-TNF-α dans le psoriasis : revue systématique et représentation graphique

Prevalence and Management of Panic Attacks during Infliximab Infusion in Psoriatic Patients

Contact Info

Product

Resources

About